InMode (NASDAQ:INMD – Get Free Report) and West Pharmaceutical Services (NYSE:WST – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership.
Volatility & Risk
InMode has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for InMode and West Pharmaceutical Services, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| InMode | 1 | 3 | 1 | 0 | 2.00 |
| West Pharmaceutical Services | 0 | 1 | 13 | 0 | 2.93 |
InMode presently has a consensus target price of $16.33, indicating a potential upside of 24.73%. West Pharmaceutical Services has a consensus target price of $424.67, indicating a potential upside of 1.89%. Given InMode’s higher possible upside, analysts plainly believe InMode is more favorable than West Pharmaceutical Services.
Earnings and Valuation
This table compares InMode and West Pharmaceutical Services”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| InMode | $373.60 million | 2.01 | $93.83 million | $1.21 | 10.82 |
| West Pharmaceutical Services | $3.40 billion | 8.55 | $493.70 million | $8.91 | 46.78 |
West Pharmaceutical Services has higher revenue and earnings than InMode. InMode is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares InMode and West Pharmaceutical Services’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| InMode | 19.94% | 11.52% | 10.16% |
| West Pharmaceutical Services | 18.81% | 21.78% | 15.99% |
Institutional & Insider Ownership
68.0% of InMode shares are owned by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are owned by institutional investors. 6.9% of InMode shares are owned by insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
West Pharmaceutical Services beats InMode on 10 of the 14 factors compared between the two stocks.
About InMode
InMode Ltd. is an Israel-based medical technology company that develops energy-based systems for minimally invasive aesthetic and medical procedures. Its technologies use radiofrequency energy to support treatments such as body contouring, skin tightening and facial rejuvenation, as well as certain women’s health applications. The company’s product portfolio includes platforms and handpieces such as BodyTite and FaceTite for body and facial contouring, and Morpheus8 for fractional radiofrequency skin treatments.
About West Pharmaceutical Services
West Pharmaceutical Services designs and manufactures packaging components and delivery systems used by the pharmaceutical, biotechnology, and medical device industries. Its products help contain and administer injectable medicines and include elastomeric components, such as stoppers and seals, as well as syringe components and other packaging and delivery solutions. The company also provides contract manufacturing services for medical devices and pharmaceutical delivery systems. Its customers include companies developing and producing branded, generic, and biologic medicines.
Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.
